Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2024, Original papers
2024

Thrombotic risk assessment in brain gliomas and meningiomas: 616.151.511/616.831-006

Original papers
Published 2024-12-10
Viktor G. Sturov
Novosibirsk National Research State University; 1 Pirogov Str., Novosibirsk 630090, Russia
ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»; Россия, 630090 Новосибирск, ул. Пирогова, 1
https://orcid.org/0000-0001-8243-247X (unauthenticated)
Oleg B. Prokhorov
Ya.L. Tsivyan Novosibirsk Research Institute of Traumatology and Orthopedics, Ministry of Health of the Russian Federation; 17 Frunze Str., Novosibirsk 630091, Russia; Federal Research Center of Fundamental and Translational Medicine; 2 Timakov Str., Novosibirsk 630117, Russia
ФГБУ «Новосибирский научно-исследовательский институт травматологии и ортопедии имени Я. Л. Цивьяна» Министерства здравоохранения Российской Федерации; Россия, 630091 Новосибирск, ул. Фрунзе, 17; ФГБНУ «Федеральный исследовательский центр фундаментальной и трансляционной медицины»; Россия, 630117 Новоcибирск, ул. Тимакова, 2
https://orcid.org/0009-0004-0336-2688 (unauthenticated)
Galina I. Moisak
Novosibirsk National Research State University; 1 Pirogov Str., Novosibirsk 630090, Russia; Federal Neurosurgical Center, Ministry of Health of the Russian Federation; 132/1 Nemirovicha-Danchenko Str., Novosibirsk 630087, Russia
ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»; Россия, 630090 Новосибирск, ул. Пирогова, 1; ФГБУ «Федеральный центр нейрохирургии» Министерства здравоохранения Российской Федерации; Россия, 630087 Новосибирск, ул. Немировича- Данченко, 132/1
https://orcid.org/0000-0002-3885-3004 (unauthenticated)
Jamil A. Rzaev
Novosibirsk National Research State University; 1 Pirogov Str., Novosibirsk 630090, Russia; Federal Neurosurgical Center, Ministry of Health of the Russian Federation; 132/1 Nemirovicha-Danchenko Str., Novosibirsk 630087, Russia
ФГАОУ ВО «Новосибирский национальный исследовательский государственный университет»; Россия, 630090 Новосибирск, ул. Пирогова, 1; ФГБУ «Федеральный центр нейрохирургии» Министерства здравоохранения Российской Федерации; Россия, 630087 Новосибирск, ул. Немировича- Данченко, 132/1
https://orcid.org/0000-0002-1209-8960 (unauthenticated)
Dmitry A. Kudlay
Sechenov University; 8 bldg. 2, Trubetskaya Str., Moscow 119991, Russia; National Research Center — Institute of Immunology, Federal Medical-B iological Agency; 24 Kashirskoye Shosse, Moscow 115522, Russia
ФГАОУ ВО Первый Московский государственный медицинский университет имени И. М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет); Россия, 119991 Москва, ул. Трубецкая, 8, стр. 2; ФГБУ «Государственный научный центр «Институт иммунологии» Федерального медико-биологического агентства»; Россия 115522 Москва, Каширское шоссе, 24
https://orcid.org/0000-0003-1878-4467 (unauthenticated)

Keywords

hypercoagulation
venous thromboembolic complications
VTEС
brain tumor
gliomas
meningiomas
D-dimer
  Full Text

Abstract

Summary. Introduction. Brain tumors are one of the predominant risk factors for the development of venous thromboembolic complications (VTEС). In particular, in gliomas, hemostasis disorders are attributable to the leading role of tissue factor and the depression of cellular activation of the fibrinolysis system. At the same time, there was virtually no assessment of the coagulation status in meningiomas. Аim: to evaluate coagulation in patients with brain gliomas and meningiomas for the prediction of microthrombotic risk. Materials and Methods.
A prospective, uncontrolled, observational, non-randomized study was conducted. Hemostasis parameters were evaluated in 43 patients with brain gliomas and 54 patients with brain meningiomas. The basic information about patients, the characteristics of tumors according to magnetic resonance imaging (MRI) findings, concomitant diseases, tumors histology, and the results of laboratory blood tests before surgery were retrospectively analyzed. The presence of thrombosis was confirmed by veins duplex scanning of the lower extremities before and after surgical treatment. Results. VTEС incidence among patients with brain tumors was 23.7%, with 25.6% among those with gliomas and 22.2% among those with meningiomas. Significant thrombotic risk factors in patients with gliomas were decreased values of international normalized ratio (INR), activated partial thromboplastin time (APTT), fibrinogen (p < 0.01), platelet count (p < 0.05) and increased prothrombin according to Quick, D-dimer level (p < 0.01) and leukocyte count (p < 0.05), increased age (p < 0.001), concomitant arterial hypertension and IDH-wildtype phenotype with increased levels of isocitrate dehydrogenase enzyme in serum (p < 0.05). In patients with meningiomas, an increase in D-dimer level (p < 0.01), older age, and the presence of concomitant obesity (p < 0.05) were identified. Spearman correlation analysis in the group with gliomas showed that an increase in D-dimer level correlated with an increase in the expression of the tumor cell nuclear proliferative activity marker Ki-67 (R = 0.532; p < 0.01) and the degree of histological tumor malignancy (Grade) according to the generally accepted scale in oncology — G rading of Recommendations Assessment, Development and Evaluation (R = 0.406; p < 0.05), while the increase in leukocytes count positively correlates with neoplasm volume (R = 0.561; p < 0.001), Grade (R = 0.428; p = 0.01) and Ki-67 (R = 0.397; p < 0.05). Conclusion. An increased VTEC risk is associated with hypercoagulability in patients with brain gliomas and meningiomas. Increased D-dimer level and leukocyte count correlate with glioma progression.

For citation: Sturov V. G., Prokhorov O. B., Moisak G. I., Rzaev J. A., Kudlay D. A. Thrombotic risk assessment in brain gliomas and meningiomas. Tromboz, gemostaz i reologiya. 2024;(4):68–80. (In Russ.).

References

  1. Anderson M. C., Shields T. W. Significance of fatal pulmonary embolism in immediate postoperative period. JAMA. 1958;167(4):422–6. DOI:10.1001/jama.1958.02990210008002.
  2. Chibbaro S., Cebula H., Todeschi J. et al. Evolution of prophylaxis protocols for venous thromboembolism in neurosurgery: results from a prospective comparative study on low-molecular-weight heparin, elastic stockings, and intermittent pneumatic compression devices. World Neurosurg. 2018;109:e510-e516. DOI: 10.1016/j. wneu.2017.10.012.
  3. Wetzel N., Anderson M. C., Shields T. W. Pulmonary embolism as a cause of death in the neurosurgical patient. J Neurosurg. 1960;17:664–8. DOI:10.3171/jns.1960.17.4.0664.
  4. Stein P. D., Beemath A., Meyers F. A. et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006;119(1):60–8. DOI: 10.1016/j.amjmed.2005.06.058.
  5. Bokeriya L. A., Zatevakhin I. I., Kirienko A. I. et al. Russian clinical guidelines for diagnosis, treatment and prevention of venous thromboembolic complications (VTEC). Flebologiya. 2015;9(4–2):1– 52. (In Russ.).
  6. Shi S., Cheng J., Chen H. et al. Preoperative and intraoperative predictors of deep venous thrombosis in adult patients undergoing craniotomy for brain tumors: а Chinese single-center, retrospective study. Thromb Res. 2020;196:245–50. DOI: 10.1016/j. thromres.2020.09.005.
  7. Bervitskiy A. V., Moisak G. I., Guzhin V. E. et al. Incidence and risk factors of venous thromboembolic events after resection of va rious brain tumors. Voprosy neurokhirurgii imeni N. N. Burdenko. 2021;85(3):63–75. (In Russ.). DOI: 10.17116/neiro20218503163.
  8. Yerrabothala S., Gourley B. L., Ford J. C. et al. Systemic coagulation is activated in patients with meningioma and glioblastoma. J Neurooncol. 2021;155(2):173–80. DOI: 10.1007/s11060-021-03865-w.
  9. Riedl J., Preusser M., Nazari P. M. et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017;129(13):1831–9. DOI: 10.1182/blood-2016-06-720714.
  10. Sciacca F. L., Ciusani E., Silvani A. et al. Genetic and plasma markers of venous thromboembolism in patients with high grade glioma. Clin Cancer Res. 2004;10(4):1312–7. DOI: 10.1158/1078-0432. CCR-03-0198.
  11. Wienkamp A. K., Erpenbeck L., Rossaint J. Platelets in the NETworks interweaving inflammation and thrombosis. Front Immunol. 2022;13:953129. DOI: 10.3389/fimmu.2022.953129.
  12. Grover S. P., Mackman N. Tissue factor: an essential mediator of hemostasis and trigger of thrombosis. Arterioscler Thromb Vasc Biol. 2018;38(4):709–25. DOI: 10.1161/ATVBAHA.117.309846.
  13. Kleindienst A., Harvey H. B., Mater E. et al. Early antithrombotic prophylaxis with low molecular weight heparin in neurosurgery. Acta Neurochir (Wien). 2003;145(12):1085–91. DOI: 10.1007/s00701-003-0142-y.
  14. Diaz M., Schiff D. Vascular complications in patients with brain tumors. Curr Opin Oncol. 2022;34(6):698–704. DOI: 10.1097/ CCO.0000000000000875.
  15. Bervitskiy A. V., Guzhin V. E., Moisak G. I. et al. Results of early administration of low molecular weight heparin for prevention of venous thromboembolism after removal of brain tumors. Neyrokhirurgiya. 2021;23(3):30–8. (In Russ.). DOI: 10.17650/1683-3295-2021-23-330-38.
  16. Navone S. E., Guarnaccia L., Locatelli M. et al. Significance and prognostic value of the coagulation profile in patients with glioblastoma: implications for personalized therapy. World Neurosurg. 2019;121: e621-e629. DOI: 10.1016/j.wneu.2018.09.177.
  17. Pishchulov K. A., Simakova M. A., Lukinov V. L. et al. Risk factors for venous thromboembolism in glioma patients. Patologiya krovoobrashcheniya i kardiohirurgiya. 2023;27(2):7–18. (In Russ.). DOI: 10.21688/1681-3472-2023-2-7-18.
  18. Thaler J., Ay C., Kaider A. et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro Oncol. 2014:16(12):1645–51. DOI: 10.1093/neuonc/ nou106.
  19. Louis D. N., Perry A., Wesseling P. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51. DOI: 10.1093/neuonc/noab106.
  20. Torregrossa F., Aguennouz M., La Torre D. et al. Role of erythropoietin in cerebral glioma: an innovative target in neuro-oncology. World Neurosurg. 2019;131:346–55. DOI: 10.1016/j.wneu.2019.06.221.
  21. Khorana A. A., Mackman N., Falanga A. et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. DOI: 10.1038/s41572-022-00336-y.
  22. Unruh D., Schwarze S. R., Khoury L. et al. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathol. 2016;132(6):917–30. DOI: 10.1007/ s00401-016-1620-7.
  23. Fiani B., Jarrah R., Bhandarkar A. R. et al. Peritumoral edema in meningiomas: pathophysiology, predictors, and principles for treatment. Clin Transl Oncol. 2023;25(4):866–72. DOI: 10.1007/ s12094-022-03009-0.
  24. Shen B. Q., Lee D. Y., Cortopassi K. M. et al. Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells. J Biol Chem. 2001;276(7):5281–6. DOI: 10.1074/jbc.M007969200.
  25. Blitshteyn S., Crook J. E., Jaeckle K. A. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol. 2008:26(2):279–82. DOI: 10.1200/JCO.2007.14.2133.
  26. Hage M., Plesa O., Lemaire I. et al. Estrogen and progesterone therapy and meningiomas. Endocrinology. 2022;163(2):bqab259. DOI: 10.1210/endocr/bqab259.